PharmaTher Announces FDA Approval of Ketamine (KETARx™)
Fabio Chianelli, Founder, Chairman and CEO of PharmaTher, commented:
'Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signalling a new era of growth. We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders.'
Ketamine stands out among psychedelic and psychedelic-adjacent drugs as the only one included on the World Health Organization's Model List of Essential Medicines1. The global ketamine market is expected to experience substantial growth, currently valued at $750 million and projected to reach $3.42 billion by 2034, indicating a compound annual growth rate of 16.4%2. Furthermore, SPRAVATO® (esketamine), an FDA approved treatment for depression, is tracking a sales run rate of $1.6 billion, with guidance anticipating $3 billion to $3.5 billion by 2027-20283. This promising market outlook underscores the potential of KETARx™ and PharmaTher's strategic position in the industry.
The FDA's approval of the Company's ketamine product, KETARx™, provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas within the Company's product pipeline. These areas include mental health conditions like depression, neurological disorders such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS), and the management of rare or chronic pain, including Complex Regional Pain Syndrome (CRPS).
Since February 2018, ketamine has been regularly listed on the FDA drug shortage list, highlighting a significant need for a consistent, high-quality supply. This issue is cautioned by a compounding risk alert issued by the FDA on October 10, 20234, which detailed potential risks associated with compounded ketamine products used for psychiatric disorders. Robert F. Kennedy Jr., Secretary of Health and Human Services, has also emphasized the importance of expanding research and ensuring legal access to psychedelic therapies for veterans5. The Veterans Health Administration, the largest integrated healthcare system in the U.S., currently approves and funds ketamine infusions for retired military personnel afflicted with depression, PTSD, and chronic pain6. Furthermore, FDA Commissioner Marty Makary's establishment of the Commissioner's National Priority Voucher program signifies the FDA's dedication to expediting access to safe and effective treatments, instilling confidence in potential future regulatory support and accessibility for ketamine.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on unlocking the pharmaceutical potential of Ketamine (KETARx™) for mental health, neurological, and pain disorders. For more information, visit PharmaTher.com.
For more information about PharmaTher, please contact:Fabio ChianelliChief Executive OfficerPharmaTher Holdings Ltd.Tel: 1-888-846-3171Email: info@pharmather.com Website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'closer', "could", 'confident', "would", "intend", "expect", "believe", "will", "projected", "estimated", "potential", 'promise', 'strong', "aim", 'may', 'plan', 'proposed', 'lead', 'toward', 'anticipate', 'provide', 'position', 'leverage', 'mitigate', 'before', 'prior', and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three and nine months ended February 28, 2025 dated April 24, 2025, which is available on the Company's profile at www.sedarplus.ca.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1
https://www.factmr.com/report/injectable-ketamine-market
https://www.proactiveinvestors.com/companies/news/1075040/spravato-sales-momentum-underscores-market-potential-for-psychedelics-atai-life-sciences-seen-as-key-beneficiary-1075040.html?region=ca®ion=ca
https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
https://www.politico.com/news/2025/06/29/rfk-psychedelics-ecstasy-ibogaine-veterans-00429997
https://rsds.org/the-veterans-health-administration-approves-and-pays-for-ketamine-infusions-for-retired-military/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
New federal entity to prioritize Canadian-made, affordable housing projects
OTTAWA — Prime Minister Mark Carney's promised new entity to spur massive amounts of housing construction will prioritize the building of affordable housing and the use of Canadian materials, says a consultation document published by the government on Monday. The document shared by Canada's housing department says Build Canada Homes is also intended to accelerate the speed at which federal lands are converted to housing, and to stress the use of materials, manufacturing and construction methods that reduce the cost and environmental impact of building. It says financial and non-financial tools being explored include loans, equity investments, real property and housing investments, loan guarantees and contributions. The department is still working on the program's design and says it's accepting feedback from the public until the end of the month. The document, released as part of a consultation process with builders and other industry stakeholders, says Build Canada Homes is positioned to support projects that deliver a "significant number" of affordable housing units. It also says the government will look at projects that expand the supply of housing run by organizations like co-ops, non-profits and Indigenous housing providers. The document says the government will look for opportunities to use Canadian-made materials and regional production hubs, and to boost the efficiency of public dollars through tools like below-market-rate loans or private or philanthropic capital. It will also prioritize projects that use new methods of construction, like prefabricated or 3D-printed construction. Housing affordability was a major issue in the recent federal election, as there haven't been enough homes built in Canada to keep up with population growth. The Canada Mortgage and Housing Corporation said in a June report that Canada needs to build between 430,000 and 480,000 new housing units over the next decade, to bring housing costs back to where they were before the pandemic. Carney promised in his election platform that his government would invest $6 billion in the Build Canada Homes initiative. The platform said Build Canada Homes would act as a developer to build affordable housing at scale, including on public lands. It also promised to provide over $25 billion in financing to prefabricated homebuilders in Canada, support affordable homebuilders and incentivize companies to hire apprentices and recent graduates by establishing new requirements on federal contribution agreements to major projects. Caroline Desrochers, parliamentary secretary to the minister of housing and infrastructure, said in a recent interview with The Canadian Press that the government is exploring options for Build Canada Homes, which could potentially become a separate agency or a unit within Housing, Infrastructure and Communities Canada. She said the government is aiming to launch the program in the fall and is "going to start doing work right now with what we have already" while exploring the best governance for the entity. Desrochers said the goal is to not create "more layers of bureaucracy and approvals." Desrochers said representatives from the government and the CMHC are on a task force created to develop the options for the new program. She said the government is also in discussion with several promoters and modular and prefabricated home companies to see what projects are ready for funding and to be built. This report by The Canadian Press was first published Aug. 11, 2025. Catherine Morrison, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Puck to drop on LeBreton Flats arena as Sens, NCC announce land sale
The Ottawa Senators and National Capital Commission say they've taken the next step toward building a major events centre. They announced they have a land sale deal, totalling approximately 11 acres at LeBreton Flats.
Yahoo
16 minutes ago
- Yahoo
Sinclair launches strategic review of broadcast unit, weighs spinoff of Ventures
(Reuters) -Sinclair said on Monday its board has authorized a strategic review of the company's broadcast business and it is considering a separation of its Ventures portfolio, sending its shares up 15% in extended trading. The review comes as media companies are exploring options for their cable TV businesses, as audiences rapidly abandon linear TV in favor of streaming platforms. Sinclair owns, operates and provides services to 178 television stations in 81 markets. The Ventures portfolio is comprised of Sinclair's private equity and real-estate assets, a cable network that includes coverage of most of tennis' top tournaments called the Tennis Channel, as well as its ad tech unit, Digital Remedy. "We expect separating Ventures will crystallize significant value that the market has overlooked within our current structure, giving us even more flexibility to drive our broadcast strategy forward," CEO Chris Ripley said. The Ventures business made nearly $11 million in minority investments during the second quarter. The company cautioned that the strategic review may not result in any transaction or change. For the quarter ended June 30, Sinclair's total revenues decreased 5% to $784 million. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
